Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.47 |
| ▸ | PPARA | Q07869 | 11/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011925 | 0.90 | PDE4B (0.47) | PPARGPPARATACR1PDE4BADAM17 | |
| SCHEMBL1014375 | 0.88 | PPARG (0.48) | PPARGPPARATACR1PDE4BNAMPT | |
| SCHEMBL2935226 | 0.88 | PPARG (0.48) | PPARGPPARATACR1PDE4BNAMPT | |
| SCHEMBL8228424 | 0.84 | CYP1A2 (0.45) | PPARGPPARA | |
| SCHEMBL1013663 | 0.81 | ACHE (0.44) | PPARGPPARATACR1ADAM17NAMPT | |
| SCHEMBL4505302 | 0.80 | JAK2 (0.53) | PPARGPPARATACR1 | |
| SCHEMBL22160548 | 0.80 | TACR1 (0.49) | TACR1ADAM17NAMPTNR1H2 | |
| SCHEMBL22160551 | 0.80 | TACR1 (0.49) | TACR1ADAM17NAMPTNR1H2 | |
| SCHEMBL22160546 | 0.80 | TACR1 (0.49) | TACR1ADAM17NAMPTNR1H2 | |
| SCHEMBL2934459 | 0.79 | STS (0.48) | PPARGPPARATACR1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272858-A2 | HCV inhibitors comprising beta amino acids and their uses | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-2007787-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | PPARG 305/4885PPARA 593/4885TACR1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.